Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVEONASDAQ:CLDXNASDAQ:FOLDNASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVEOAVEO Pharmaceuticals$15.00$14.97$3.06▼$15.00$521.45M1601,442 shs247,800 shsCLDXCelldex Therapeutics$21.35+9.3%$18.98$14.40▼$47.00$1.42B1.33918,647 shs852,592 shsFOLDAmicus Therapeutics$6.16+3.4%$6.61$5.81▼$12.65$1.90B0.542.94 million shs5.15 million shsLGNDLigand Pharmaceuticals$105.99+1.7%$104.32$77.43▼$129.90$2.04B0.83115,851 shs91,810 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVEOAVEO Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CLDXCelldex Therapeutics0.00%+9.54%+9.38%+3.29%-35.32%FOLDAmicus Therapeutics0.00%+0.82%+1.32%-30.47%-41.22%LGNDLigand Pharmaceuticals0.00%+2.73%+3.39%-7.70%+26.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACLDXCelldex Therapeutics1.9778 of 5 stars4.50.00.00.03.50.00.0FOLDAmicus Therapeutics3.8917 of 5 stars3.41.00.04.32.40.01.9LGNDLigand Pharmaceuticals4.8122 of 5 stars3.53.00.04.43.53.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVEOAVEO Pharmaceuticals 0.00N/AN/AN/ACLDXCelldex Therapeutics 2.90Moderate Buy$53.90152.46% UpsideFOLDAmicus Therapeutics 2.70Moderate Buy$16.22163.35% UpsideLGNDLigand Pharmaceuticals 3.00Buy$146.1437.88% UpsideCurrent Analyst Ratings BreakdownLatest AVEO, LGND, FOLD, and CLDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025CLDXCelldex TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.005/9/2025CLDXCelldex TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $31.005/9/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$46.00 ➝ $43.005/9/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.005/6/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.005/2/2025FOLDAmicus TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$12.00 ➝ $9.004/28/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$64.004/10/2025LGNDLigand PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$143.003/20/2025CLDXCelldex TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$46.00(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVEOAVEO Pharmaceuticals$42.29M12.33N/AN/A$1.33 per share11.28CLDXCelldex Therapeutics$7.56M187.50N/AN/A$9.08 per share2.35FOLDAmicus Therapeutics$543.14M3.49N/AN/A$0.63 per share9.78LGNDLigand Pharmaceuticals$181.49M11.27$4.35 per share24.39$40.39 per share2.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVEOAVEO Pharmaceuticals-$53.34M-$0.84N/A28.85N/A-30.79%-81.66%-28.83%N/ACLDXCelldex Therapeutics-$141.43M-$2.70N/AN/AN/A-1,544.32%-19.75%-18.86%8/6/2025 (Estimated)FOLDAmicus Therapeutics-$151.58M-$0.09N/A14.331.51-10.62%12.44%2.60%8/14/2025 (Estimated)LGNDLigand Pharmaceuticals$52.15M-$7.1242.2328.57N/A29.68%4.95%4.39%8/5/2025 (Estimated)Latest AVEO, LGND, FOLD, and CLDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CLDXCelldex Therapeutics-$0.75-$0.81-$0.06-$0.81$1.08 million$0.70 million5/8/2025Q1 2025LGNDLigand Pharmaceuticals$1.23$1.33+$0.10-$2.21$37.84 million$45.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVEOAVEO PharmaceuticalsN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVEOAVEO Pharmaceuticals0.942.372.35CLDXCelldex TherapeuticsN/A24.2724.27FOLDAmicus Therapeutics2.013.392.42LGNDLigand PharmaceuticalsN/A12.4911.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVEOAVEO Pharmaceuticals49.95%CLDXCelldex TherapeuticsN/AFOLDAmicus TherapeuticsN/ALGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipAVEOAVEO Pharmaceuticals3.29%CLDXCelldex Therapeutics3.80%FOLDAmicus Therapeutics2.20%LGNDLigand Pharmaceuticals5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVEOAVEO Pharmaceuticals11434.76 million33.62 millionOptionableCLDXCelldex Therapeutics15066.38 million63.82 millionOptionableFOLDAmicus Therapeutics480307.93 million292.23 millionOptionableLGNDLigand Pharmaceuticals8019.29 million17.78 millionOptionableAVEO, LGND, FOLD, and CLDX HeadlinesRecent News About These CompaniesLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Congress Asset Management Co.June 7 at 6:48 AM | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 1,000 SharesJune 3, 2025 | marketbeat.comAndrew Reardon Sells 1,000 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockJune 3, 2025 | insidertrades.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.40 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 3, 2025 | marketbeat.comSummit Global Investments Acquires 6,407 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)June 1, 2025 | marketbeat.comKings Path Partners LLC Reduces Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 31, 2025 | marketbeat.comSquarepoint Ops LLC Purchases Shares of 16,799 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 31, 2025 | marketbeat.comBank of America Corp DE Purchases 2,533 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 25, 2025 | marketbeat.comCastleark Management LLC Cuts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 23, 2025 | marketbeat.comGraham Capital Management L.P. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 18, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by BrokeragesMay 18, 2025 | marketbeat.comDeutsche Bank AG Purchases 15,160 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 16, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 5,929 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 15, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Downgraded to Sell Rating by StockNews.comMay 15, 2025 | marketbeat.comLigand to Ring the Nasdaq Opening Bell on May 19, 2025May 14, 2025 | globenewswire.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Acquires $156,090.00 in StockMay 14, 2025 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Northern Trust CorpMay 13, 2025 | marketbeat.comLGND: 1Q:25 ResultsMay 12, 2025 | msn.comClark Capital Management Group Inc. Increases Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 12, 2025 | marketbeat.comDriehaus Capital Management LLC Increases Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 11, 2025 | marketbeat.comBaird Financial Group Inc. Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)May 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVEO, LGND, FOLD, and CLDX Company DescriptionsAVEO Pharmaceuticals NASDAQ:AVEOAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Celldex Therapeutics NASDAQ:CLDX$21.35 +1.82 (+9.32%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$21.68 +0.33 (+1.54%) As of 06/6/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Amicus Therapeutics NASDAQ:FOLD$6.16 +0.20 (+3.36%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$6.19 +0.03 (+0.50%) As of 06/6/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ligand Pharmaceuticals NASDAQ:LGND$105.99 +1.81 (+1.74%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$106.08 +0.09 (+0.08%) As of 06/6/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Five Below Pops on Strong Earnings, But Rally May Stall Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
